India’s Pharmacy Council of India (PCI) has notified Medical Devices as a new M.Pharm specialisation under the Master of Pharmacy (M.Pharm) Course Regulations, 2014. Starting academic year 2027-28, pharmacy graduates can pursue an M.Pharm in medical devices focused entirely on device technology, regulatory affairs, quality systems, and clinical evaluation. On paper, this is a direct response to a workforce gap that every medtech manufacturer in India already knows about. Whether it actually closes that gap depends on execution, and on questions PCI’s notification does not answer.
As covered in India’s Medtech 2025, the sector grew 10-12% last year on the strength of policy movement. An education system catching up is the next step, and this notification is where it starts.
🎯 Key Insight
PCI’s notification is the first formal academic pathway that produces pharmacy graduates with structured training in device regulatory affairs, quality systems, and clinical evaluation. Until now, those skills were acquired on the job or through short courses. Whether the course closes India’s medtech skill gap depends on execution details the notification does not settle.
What PCI Has Actually Notified
The PCI, constituted under the Pharmacy Act, 1948 (Section 10), has the statutory authority to prescribe minimum education standards for pharmacy qualifications and approve courses of study (Section 12). Under this mandate, PCI has added Medical Devices as the eleventh specialisation in the Revised Regulations for the Master of Pharmacy Degree Programme, Credit Based Semester System (CBSS).
The existing M.Pharm framework already covers ten specialisations: Pharmaceutics, Industrial Pharmacy, Pharmaceutical Chemistry, Pharmaceutical Analysis, Pharmaceutical Quality Assurance, Regulatory Affairs, Pharmaceutical Biotechnology, Pharmacy Practice, Pharmacology, and Pharmacognosy. Medical Devices is the first to sit deliberately at the boundary between pharmacy, engineering, and healthcare technology.
The expert committee met at PCI, New Delhi on 19 February 2026 to finalise the draft syllabus. The scheme and syllabus were notified in August 2026, with implementation from the 2027-28 academic session.
The Course Structure: Semester by Semester
The M.Pharm in Medical Devices follows the standard four-semester, two-year PCI framework with a minimum of 95 credit points, up to 100 including co-curricular activities. The first two semesters carry the specialised device-focused content; the third and fourth are dominated by research work common to all M.Pharm specialisations.
Semester I covers the foundations:
- Basics of medical device technology (100 marks)
- Regulatory affairs of medical devices (100 marks)
- Medical device manufacturing (100 marks)
- Medical device biocompatibility and toxicology (100 marks)
- Medical device technology lab I (150 marks)
- Seminar and assignments (100 marks)
Semester II moves into applied and advanced territory:
- Medical device innovations and emerging technologies (100 marks)
- Medical device quality control (100 marks)
- Risk assessment and safety management (100 marks)
- Clinical evaluation and market access of medical devices (100 marks)
- Ethics, IPR, and entrepreneurship in medical devices (100 marks)
- Medical device technology lab II (150 marks)
- Seminar and assignments (100 marks)
Semesters III and IV follow the standard M.Pharm research structure: research methodology and biostatistics, journal club, proposal presentation, and research work, common across all specialisations.
The research component can be conducted at the parent institution or at external organisations with recognised medical device research facilities. PCI explicitly lists eligible partners (CDSCO oversees India’s device regulation — cdsco.gov.in):
| External Partner Type | Approval Requirement |
|---|---|
| Medical device industries | Approved by CDSCO |
| Device testing laboratories | Recognised by national regulatory authorities |
| Institutes of national importance | As designated |
| Hospitals | Approved by Indian Pharmacopoeia Commission as materiovigilance centres |
| Government research laboratories | Eligible as listed |
| CROs and R&D laboratories | Accredited clinical research organisations |
Institutions must execute a legally valid MoU with the partner in PCI’s prescribed format.
Why This Specialisation, Why Now
Two forces are converging, and both are visible in the data.
First, the regulatory framework has expanded. India’s medical device sector grew at 10-12% year-over-year to reach USD 17.5 billion in 2025, with PLI scheme sales of Rs 8,040 crore and 22 commissioned manufacturing projects. As we noted in our India’s Medtech 2025 analysis, the government recognised medtech as a distinct sector deserving its own regulatory frameworks, not an afterthought in broader pharma policy. CDSCO has been progressively bringing device categories under formal regulatory control, which creates demand for professionals who understand both device technology and the regulatory process. That combination has been genuinely scarce.
Second, the skill gap is measurable. A KPMG report cited by industry analysis in February 2025 found that India has a 40% deficit in skilled biomedical engineering, biotechnology, regulatory affairs, and manufacturing technology professionals. India imports nearly 70% of its medical equipment, USD 8 billion in imports against USD 4 billion in exports in 2023-24. The country’s healthcare R&D spending sits below 0.5% of GDP, compared to 8-10% of revenues in countries like the US and Germany.
PCI’s notification is, in effect, an education-system response to a gap that industry has been reporting for years. The Materiovigilance Programme of India, which monitors adverse events from medical devices, has further brought device safety into the conceptual space that pharmacists already occupy with pharmacovigilance. The new B.Pharm 2026 syllabus includes Materiovigilance and Hemovigilance as a Semester VI elective. Medical devices are no longer outside pharmacy’s professional scope.
Eligibility and Colleges: Who Can Apply
This is the section most students and professionals miss.
Eligibility for students: B.Pharm degree from a PCI-approved institution, minimum 55% aggregate across four years (50% for SC/ST/reserved categories), and GPAT score or the relevant state entrance examination as prescribed by the admitting university.
Institutional eligibility is tighter. Under PCI’s M.Pharm approval scheme, institutions approved only for B.Pharm cannot start an M.Pharm course. The exception is institutions established by the Central or State Government specifically for postgraduate education. Institutions already running approved M.Pharm programmes must obtain prior PCI permission before adding the Medical Devices specialisation or increasing intake.
Practically, this means M.Pharm (Medical Devices) will initially be available at a limited number of institutions, those with existing M.Pharm approval and the willingness to invest in the additional infrastructure a device programme requires: labs, industry MoUs, faculty with device expertise. Do not assume every pharmacy college will offer it.
Career Prospects in Medical Device Regulatory Affairs
This is where readers need to think carefully, because enthusiasm around a new course rarely matches the job market in its first few years.
Where the genuine opportunities exist:
- Regulatory affairs (devices) – device registration, technical documentation, CDSCO submissions. Real and growing demand as more device categories come under regulatory control.
- Quality assurance and quality systems in device manufacturing – ISO 13485 implementation, process validation, post-market surveillance.
- Materiovigilance and post-market surveillance – the closest natural fit to existing pharmacy training, building on pharmacovigilance skills.
- Clinical evaluation and clinical affairs for device manufacturers – preparing clinical evidence for regulatory submissions.
- Academia – as institutions start this programme, they will need faculty who hold the qualification.
Where caution is warranted:
No job role in India is currently reserved for an M.Pharm (Medical Devices) graduate. Employers in the device sector have historically hired biomedical engineers, B.Tech graduates, and experienced regulatory professionals for these roles. This qualification will have to earn recognition in the market. It has not been handed any.
The first M.Pharm medical devices cohort graduates in 2029. They will be explaining what their degree is to recruiters who have never seen it. That can work in their favour if the sector grows as expected, and against them if it does not.
Faculty capability is an open question. Very few pharmacy departments currently have staff with device technology or device regulatory expertise. Before choosing an institution, ask specifically who will teach the core device papers and what their background is. The course structure on paper is strong. The delivery depends on whether institutions can find qualified faculty.
Critical Caveat
No reserved job role exists yet for this qualification, and faculty supply is unproven. The institutions that invest in real device expertise will produce graduates worth hiring. The ones that treat it as a paperwork exercise will not.
What This Means for India’s Medical Device Industry
The broader significance goes beyond individual career decisions.
India’s medtech sector is at an inflection point. The PLI scheme proved manufacturing scale is possible. CDSCO’s regulatory convergence with IMDRF demonstrated international credibility is attainable. But the workforce constraint has been a structural bottleneck: you cannot build a domestic medtech industry on imported talent alone.
PCI’s M.Pharm in Medical Devices is one piece of a multi-pronged response that should include:
- Dedicated medtech skill centres bridging theoretical knowledge and practical expertise
- Industry-academia partnerships between institutions like IIT, IISc, NIPER, AIIMS and medtech companies
- NSDC-led vocational training for technicians and QA professionals in device manufacturing and regulatory compliance
- Tax incentives for companies investing in training and skill development
The 40% skilled workforce deficit will not be closed by one M.Pharm medical devices specialisation alone. But it is the first formal academic pathway that produces pharmacy graduates with structured training in device regulatory affairs, quality systems, and clinical evaluation: skills that until now were acquired through on-the-job experience or short courses.
The Gaps This Course Does Not Fill
PCI’s notification is a positive step, but three gaps remain:
1. No reserved job role
Unlike clinical pharmacist positions that PCI has pushed for in hospitals, M.Pharm (Medical Devices) has no corresponding recruitment rule or designated position. Employers will hire based on skills, not degree title, at least initially.
2. Faculty supply
The course assumes pharmacy departments can teach device technology, manufacturing, and biocompatibility. Most cannot, not yet. The institutions that invest in faculty with real device industry experience will produce graduates worth hiring. The ones that treat it as a paperwork exercise will not.
3. Industry integration
The MoU-based research model is sound on paper. Whether institutions actually execute meaningful research partnerships with CDSCO-approved device manufacturers, rather than signing MoUs that exist only on paper, will determine whether graduates emerge with practical exposure or just a syllabus-compliant degree.
For B.Pharm graduates weighing this specialisation: consider it if you are specifically interested in regulatory affairs or quality systems, comfortable being early to a field, and have access to an institution with real device expertise and industry linkage. Think harder if you want predictable placement outcomes or are choosing purely because the name sounds modern.
M.Pharm (Regulatory Affairs), (Pharmacy Practice), and (Pharmacology) remain safer choices in terms of established recruitment patterns. That is not an argument against Medical Devices. It is an argument for going in with clear eyes.
Frequently Asked Questions
What is M.Pharm in Medical Devices?
It is a two-year, four-semester postgraduate specialisation notified by PCI under the M.Pharm Credit Based Semester System regulations. Starting 2027-28, it covers device technology, regulatory affairs, manufacturing, biocompatibility, quality control, and clinical evaluation, with a minimum of 95 credit points.
Who is eligible for M.Pharm in Medical Devices?
B.Pharm graduates from PCI-approved institutions with at least 55% aggregate (50% for reserved categories) and a valid GPAT or state entrance score. Whether Pharm.D graduates qualify is not yet confirmed in the notification; check the PCI gazette before applying.
Which colleges will offer this course?
Only institutions that already hold PCI approval for M.Pharm programmes can add the Medical Devices specialisation, and they need prior PCI permission. Expect a limited number of colleges in the first years, prioritising those with device labs, faculty, and industry MoUs.
What are the career prospects after M.Pharm in Medical Devices?
Device regulatory affairs, quality assurance (ISO 13485), materiovigilance, clinical evaluation, and academia are the main paths. Demand is growing, but no Indian job role is reserved for this degree yet, so the qualification must prove itself in the market.
Exploring a career in device regulatory affairs? See how Regulatory Frontier guides medtech teams through CDSCO, EU MDR, and FDA pathways.
Sources
Pharmacy Council of India, pci.gov.in